Cannovum AG

  • WKN: A2LQU2
  • ISIN: DE000A2LQU21
  • Land: Deutschland

Nachricht vom 24.06.2021 | 09:06

Cannovum AG enters supply agreement for medical cannabis with Aurora Europe

DGAP-News: Cannovum AG / Key word(s): Product Launch
24.06.2021 / 09:06
The issuer is solely responsible for the content of this announcement.

Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has entered into a long term supply agreement with Aurora through its licensed subsidiary, Cannovum Health eG. Starting today, Cannovum will distribute the full range of medical cannabis products offered by Aurora to pharmacies throughout Germany.

The canadian company Aurora is one of the largest authorised manufacturers of medical cannabis in the European Union. After the German legalization of medical cannabis in 2017 Aurora joined the German market with their acquisition of the German company Pedanios, thus making Aurora / Pedanios products one of the first cannabis medicines available in Germany. This allowed doctors and pharmacists to gain experience in treating their patients with these products.
Expanding the medical cannabis portfolio with the full range of Aurora products is therefore an important step for Cannovum towards ensuring best possible patient care.

"We want to support doctors and pharmacists in finding the appropriate treatment for their patients. In order for us to achieve that, we need to provide a full portfolio of medical cannabis which gives them the opportunity to fully customize the therapy. By partnering with Aurora we are confident that we continue to provide high quality medication to ensure every patient receives the best therapy", says Pia Marten, CEO of Cannovum AG.

Cannovum's own team of pharmaceutical representatives has received intensive training in the new products, in order to confidently advise pharmacists and doctors.


Contact:

Linda Rasch, IR & PR, Cannovum AG
Phone +49 30 3982 163 62, linda.rasch@cannovum.com

Cannovum AG is the first German listed medical cannabis company. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing distribution for simplified and facilitated access to cannabis-based therapies.

For more information, visit www.cannovum.com



24.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

IPO im Fokus

MIT SICHERHEIT AUFS PARKETT. UNSER BÖRSENGANG ZUR WACHSTUMSBESCHLEUNIGUNG

ISIN: DE000A3CM708
Grundkapital (vor IPO): 3.120.000 EUR
Angebotene Aktien: bis zu 690.000 Aktien
Zeichnungsfrist: 11.10.2021 bis voraus. 25.10.2021
Bookbuildingspanne: 3,30 bis 3,60 Euro
Börse: Börse Düsseldorf

Rechtlich maßgeblicher Wertpapierprospekt auf sdm-se.de

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC im Fokus

Börsengang sdm SE: Attraktives Investment

Der Sicherheitsdienstleister sdm SE führt derzeit einen Börsengang am Primärmarkt der Börse Düsseldorf durch. Die Mittel des Börsengangs sollen die Wachstumsstrategie finanzieren und die Ertragskraft deutlich steigern. Im Rahmen unseres DCF-Bewertungsmodells haben wir einen fairen Unternehmenswert (Post Money) zum Ende des Geschäftsjahres 2022 in Höhe von 15,23 Mio. € bzw. 4,09 € je sdm-Aktie ermittelt. Unter einem Preis von 3,50 € pro Aktie sehen wir sdm als ein attraktives Investment und stufen die Aktie mit dem Rating „Kaufen“ ein.

News im Fokus

Continental passt Ausblick für das Geschäftsjahr 2021 an und veröffentlicht vorläufige Kennzahlen für das dritte Quartal 2021

22. Oktober 2021, 14:11

Aktueller Webcast

TRATON SE

Pressekonferenz – Zwischenmitteilung 9M 2021 - Webcast

28. Oktober 2021

Aktuelle Research-Studie

Aves One AG

Original-Research: Aves One AG (von GBC AG): Halten

21. Oktober 2021